1 Reason Every Investor Should Know About Novo Nordisk (NVO)

Novo Nordisk is poised to potentially reclaim market leadership in the weight loss drug segment with its oral Wegovy, which demonstrated superior efficacy (15.1% body weight reduction) in Phase 3 trials compared to Eli Lilly's oral candidate orforglipron (12.4%). This development follows Eli Lilly's injectable Zepbound currently outperforming Novo Nordisk's Wegovy due to efficacy and supply constraints. An FDA decision for oral Wegovy is expected in Q4 2025, and its potential approval could significantly shift market dynamics by introducing a highly effective and convenient oral alternative.

Analysis

The competitive landscape in the lucrative weight loss drug market is poised for a significant shift, with Novo Nordisk (NVO) positioned to challenge Eli Lilly's (LLY) recent gains. While LLY's injectable Zepbound has been capturing market share from NVO's Wegovy, attributed to superior efficacy and NVO's supply constraints, the next front in this battle is oral medication. Novo Nordisk's pipeline appears to hold a strategic advantage here. Phase 3 trial data for its oral version of Wegovy demonstrated a 15.1% reduction in body weight, outperforming the 12.4% reduction shown by Eli Lilly's oral candidate, orforglipron. The convenience of an oral drug, coupled with potentially superior efficacy, could allow NVO to reclaim significant market leadership. The key catalyst is the FDA's decision on oral Wegovy, which has been accepted for review and is expected in the fourth quarter of 2025, making this a critical milestone for a potential re-rating of the company's growth outlook.

Key Decisions for Investors

• Investors with a long-term horizon in Novo Nordisk should view the upcoming oral Wegovy as a primary catalyst that could disrupt the current market structure and reverse recent share losses to Eli Lilly.
• The pending FDA decision in Q4 2025 introduces a significant binary event risk; therefore, positions in NVO should be sized according to an investor's tolerance for regulatory outcomes.
• Holders of Eli Lilly should monitor developments in Novo Nordisk's oral drug pipeline, as the introduction of a more effective and convenient competitor poses a direct threat to Zepbound's long-term revenue projections post-2025.
• Monitor any updates on Novo Nordisk's manufacturing and supply chain capacity, as its ability to meet anticipated high demand for an oral drug will be critical to capitalizing on a potential FDA approval.